2014 | Alcon Canada Inc. | Ilevro - 3 mg/ml | nepafenac | 02411393 | Pain | 6 Jul 2014 | Within Guidelines |
2014 | Pfizer Canada Inc. | Elelyso - 200 unit/vial | taliglucerase alfa | 02425637 | Gaucher disease | 8 Sep 2014 | Within Guidelines |
2014 | Valeant Canada Lp | Vyloma - 250 mg/pouch | imiquimod | 02365561 | Genital warts | 9 Dec 2011 (patented 13 May 2014) | Within Guidelines |
2014 | Abbott Laboratories Limited | Creon Minimicrospheres - 6000 unit/capsule | pancreatin | 02415194 | Pancreatic exocrine insufficiency | 22 Dec 2013 | Within Guidelines |
2014 | Actavis Specialty Pharmaceuticals Co. | Lolo 1/0.1 | norethindrone acetate/ethinyl estradiol | 02417456 | Contraceptive | 24 Mar 2014 | Within Guidelines |
2014 | Actavis Specialty Pharmaceuticals Co. | Constella - 290 mcg/capsule | linaclotide | 02417162 | Irritable bowel syndrome | 27 Nov 2014 | Within Guidelines |
2014 | Actavis Specialty Pharmaceuticals Co. | Constella - 145 mcg/capsule | linaclotide | 02417162 | Irritable bowel syndrome | 1 May 2014 | Within Guidelines |
2014 | Actavis Specialty Pharmaceuticals Co. | Fibristal - 5 mg/tablet | ulipristal acetate | 02408163 | Selective Progesterone Receptor Modulator | 04 Jul 2014 | Subject to Investigation |
2014 | Actelion Phamaceuticals Canada Inc. | Caripul - 0.5 mg/vial | epoprostenol sodium | 02397447 | Hypertension | 24 Apr 2014 (patented 16 Dec 2014) | Within Guidelines |
2014 | Actelion Phamaceuticals Canada Inc. | Caripul - 1.5 mg/vial | epoprostenol sodium | 02397455 | Hypertension | 24 Apr 2014 (patented 16 Dec 2014) | Within Guidelines |
2014 | Actelion Phamaceuticals Canada Inc. | Xiaflex - 0.9 mg/vial | collagenase clostridium histolyticum | 02388316 | Dupuytren’s contracture | 15 Apr 2013 (patented 19 Aug 2014) | Within Guidelines |
2014 | Actelion Phamaceuticals Canada Inc. | Opsumit - 10 mg/tablet | macitentan | 02415690 | Pulmonary arterial hypertension | 15 Jan 2014 | Within Guidelines |
2014 | Aegerion Pharmaceuticals (Canada) Ltd. | Juxtapid - 5 mg/capsule | lomitapide | 02420341 | Microsomal Triglyceride Transfer Protein Inhibitor | 6 May 2014 | Within Guidelines |
2014 | Aegerion Pharmaceuticals (Canada) Ltd. | Juxtapid - 10 mg/capsule | lomitapide | 02420376 | Microsomal Triglyceride Transfer Protein Inhibitor | 6 May 2014 | Within Guidelines |
2014 | Aegerion Pharmaceuticals (Canada) Ltd. | Juxtapid - 20 mg/capsule | lomitapide | 02420384 | Microsomal Triglyceride Transfer Protein Inhibitor | 6 May 2014 | Within Guidelines |
2014 | AstraZeneca Canada Inc. | FluMist Quadrivalent - 0.2 unit/dose | influenza vaccine | 02426544 | Influenza | 10 Oct 2014 | Within Guidelines |
2014 | Bayer Inc. | Xofigo - 1000 kilobecquerel/ml | radium Ra 223 dichloride | | Prostate Cancer | 29 Aug 2014 | Within Guidelines |
2014 | Bayer Inc. | Eylea - 40 mg/ml | aflibercept | 02415992 | Neovascular (wet) age-related macular degeneration | 23 Dec 2013 | Within Guidelines |
2014 | Biogen Idec Canada Inc. | Tecfidera - 240 mg/capsule | dimethyl fumarate | 02420201 | Multiple sclerosis | 5 May 2014 | Subject to Investigation |
2014 | Boehringer Ingelheim (Canada) Ltd. | Giotrif - 20 mg/tablet | afatinib | 02415666 | Protein Kinase Inhibitor | 17 Jan 2014 | Within Guidelines |
2014 | Boehringer Ingelheim (Canada) Ltd. | Giotrif - 30 mg/tablet | afatinib | 02415674 | Protein Kinase Inhibitor | 17 Jan 2014 | Within Guidelines |
2014 | Boehringer Ingelheim (Canada) Ltd. | Giotrif - 40 mg/tablet | afatinib | 02415682 | Protein Kinase Inhibitor | 17 Jan 2014 | Within Guidelines |
2014 | Celgene Inc. | Pomalyst - 1 mg/capsule | pomalidomide | 02419580 | Multiple myeloma | 21 Feb 2014 | Within Guidelines |
2014 | Celgene Inc. | Pomalyst - 2 mg/capsule | pomalidomide | 02419599 | Multiple myeloma | 21 Feb 2014 | Within Guidelines |
2014 | Celgene Inc. | Pomalyst - 3 mg/capsule | pomalidomide | 02419602 | Multiple myeloma | 21 Feb 2014 | Within Guidelines |
2014 | Celgene Inc. | Pomalyst - 4 mg/capsule | pomalidomide | 02419610 | Multiple myeloma | 26 Feb 2014 | Within Guidelines |
2014 | Celgene Inc. | Istodax - 10 mg/vial | romidepsin | 02414295 | Peripheral T-cell lymphoma | 3 Apr 2014 | Within Guidelines |
2014 | Ferring Pharmaceuticals Inc. | Nocdurna - 50 mcg/tablet | desmopressin acetate | 02431076 | Nocturia | 17 Nov 2014 | Within Guidelines |
2014 | Galderma Canada Inc. | Onreltea - 5 mg/g | brimonidine | 02421208 | Rosacea | 24 Mar 2014 | Subject to Investigation |
2014 | GenMed | GD-Quinapril - 40 mg/tablet | quinapril | 02291010 | Hypertension | 2 Jun 2014 | Within Guidelines |
2014 | GenMed | GD-Celecoxib - 100 mg/capsule | celecoxib | 02291975 | Arthritis | 20 Nov 2014 | Within Guidelines |
2014 | GenMed | GD-Celecoxib - 200 mg/capsule | celecoxib | 02291983 | Arthritis | 20 Nov 2014 | Within Guidelines |
2014 | GenMed | GD-Quinapril - 5 mg/tablet | quinapril | 02290987 | Hypertension | 2 Jun 2014 | Within Guidelines |
2014 | GenMed | GD-Quinapril - 10 mg/tablet | quinapril | 02290995 | Hypertension | 2 Jun 2014 | Within Guidelines |
2014 | GenMed | GD-Quinapril - 20 mg/tablet | quinapril | 02291002 | Hypertension | 2 Jun 2014 | Within Guidelines |
2014 | GenMed | GD-Azithromycin - 20 mg/ml | azithromycin | 02274566 | Antibiotic | 9 Dec 2013 | Within Guidelines |
2014 | GenMed | GD-Azithromycin - 40 mg/ml | azithromycin | 02274574 | Antibiotic | 9 Dec 2013 | Within Guidelines |
2014 | Gilead Sciences Inc. | Harvoni 90/400 - 490 mg/tablet | ledipasvir/sofosbuvir | 02432226 | Hepatitis C | 16 Oct 2014 | Within Guidelines |
2014 | Gilead Sciences Inc. | Sovaldi - 400 mg/tablet | sofosbuvir | 02418355 | Chronic hepatitis C virus | 6 Jan 2014 | Within Guidelines |
2014 | Glaxosmithkline Inc. | Rotarix - 1 n.a./dose | rotavirus vaccine | 02300591 | Vaccine | 17 Dec 2008 (patented 8 July 2014) | Within Guidelines |
2014 | Glaxosmithkline Inc. | Anoro Ellipta 62.5/25 - 87.5 mcg/dose | umeclidinium bromide/vilanterol | 02418401 | Chronic obstructive pulmonary disease | 14 Mar 2014 | Within Guidelines |
2014 | Hoffmann-La Roche Limited, Canada | Actemra 162 mg/syringe | tocilizumab | 02424770 | Rheumatoid Arthritis | 30 May 2014 | Within Guidelines |
2014 | Hoffmann-La Roche Limited, Canada | Gazyva - 25 mg/mL | obinutuzumab | 02434806 | Leukemia | 28 Nov 2014 | Does Not Trigger Investigation |
2014 | Janssen Inc. | Imbruvica - 140 mg/capsule | ibrutinib | 02434407 | Leukemia | 25 Nov 2014 | Within Guidelines |
2014 | Janssen Inc. | Invokana - 100 mg/tablet | canagliflozin | 02425483 | Diabetes | 4 Jun 2014 | Does Not Trigger Investigation |
2014 | Janssen Inc. | Nucynta Extended Release - 100 mg/tablet | tapentadol hydrochloride | 02415585 | Pain | 21 Apr 2014 | Within Guidelines |
2014 | Janssen Inc. | Nucynta Extended Release - 150 mg/tablet | tapentadol hydrochloride | 02415593 | Pain | 21 Apr 2014 | Within Guidelines |
2014 | Janssen Inc. | Nucynta Extended Release - 200 mg/tablet | tapentadol hydrochloride | 02415607 | Pain | 21 Apr 2014 | Within Guidelines |
2014 | Janssen Inc. | Nucynta Extended Release - 250 mg/tablet | tapentadol hydrochloride | 02415615 | Pain | 21 Apr 2014 | Within Guidelines |
2014 | Janssen Inc. | Nucynta Extended Release - 50 mg/tablet | tapentadol hydrochloride | 02415577 | Pain | 21 Apr 2014 | Within Guidelines |
2014 | Janssen Inc. | Simponi - 50 mg/vial | golimumab | 02417472 | Rheumatoid Arthritis | 30 Dec 2013 | Within Guidelines |
2014 | Janssen Inc. | Prezcobix 800/150 - 950 mg/tablet | darunavir/cobicistat | 02426501 | HIV | 29 Aug 2014 | Within Guidelines |
2014 | Janssen Inc. | Invokana - 300 mg/tablet | canagliflozin | 02425491 | Diabetes | 28 May 2014 | Within Guidelines |
2014 | Lundbeck Canada Inc. | Trintellix - 5 mg/tablet | vortioxetine hydrobromide | 02432919 | Antidepressant | 27 Nov 2014 | Within Guidelines |
2014 | Lundbeck Canada Inc. | Trintellix - 10 mg/tablet | vortioxetine hydrobromide | 02432927 | Antidepressant | 27 Nov 2014 | Within Guidelines |
2014 | Lundbeck Canada Inc. | Trintellix - 20 mg/tablet | vortioxetine hydrobromide | 02432943 | Antidepressant | 27 Nov 2014 | Within Guidelines |
2014 | Merck Canada Inc. | Ragwitek - 12 unit/tablet | Standardized Allergen Extract, Short Ragweed (Ambrosia artemisiifolia) | 02423723 | Allergy immunotherapy | 29 Apr 2014 | Within Guidelines |
2014 | Merck Canada Inc. | Posanol - 100 mg/tablet | posaconazole | 02424622 | Antifungal Agent | 21 May 2014 | Does Not Trigger Investigation |
2014 | Merck Canada Inc. | Janumet XR 50/1000 - 1050 mg/tablet | sitagliptin phosphate monohydrate/metformin hydrochloride | 02416794 | Diabetes | 15 Jan 2014 | Within Guidelines |
2014 | Merck Canada Inc. | Grastek - 2800 unit/tablet | standardized allergenic extract, timothy grass (pleum pratense) | 02418394 | Allergy Immunotherapy | 13 Jan 2014 | Within Guidelines |
2014 | Merck Canada Inc. | Posanol - 300 mg/vial | posaconazole | 0242462 | Antifungal Agent | 24 Nov 2014 | Subject to Investigation |
2014 | Novartis Pharmaceuticals Canada Inc. | Bexsero - 1 n.a./dose | multicomponent meningococcal B vaccine | 02417030 | Vaccine | 25 Feb 2014 | Within Guidelines |
2014 | Novartis Pharmaceuticals Canada Inc. | Lucentis - 0.5 mg/dose | ranibizumab | 02425629 | Neovascular (wet) Age-Related Macular Degeneration | 18 Sep 2014 | Within Guidelines |
2014 | Novartis Pharmaceuticals Canada Inc. | Afinitor Disperz - 2 mg/tablet | everolimus | 02425645 | Cancer | 28 Nov 2014 | Within Guidelines |
2014 | Novartis Pharmaceuticals Canada Inc. | Afinitor Disperz - 3 mg/tablet | everolimus | 02425653 | Cancer | 28 Nov 2014 | Within Guidelines |
2014 | Novartis Pharmaceuticals Canada Inc. | Afinitor Disperz - 5 mg/tablet | everolimus | 02425661 | Cancer | 28 Nov 2014 | Within Guidelines |
2014 | Novartis Pharmaceuticals Canada Inc. | Ultibro Breezhaler 110/50 - 160 mcg/capsule | indacaterol maleate/glycopyrronium bromide | 02418282 | Chronic obstructive pulmonary disease | 5 Mar 2014 | Within Guidelines |
2014 | Novo Nordisk Canada Inc. | Norditropin NordiFlex - 5 mg/pen | somatropin | 02334852 | Growth hormone deficiency | 21 Aug 2014 | Within Guidelines |
2014 | Novo Nordisk Canada Inc. | Norditropin NordiFlex - 10 mg/pen | somatropin | 02334860 | Growth hormone deficiency | 21 Aug 2014 | Within Guidelines |
2014 | Novo Nordisk Canada Inc. | Norditropin NordiFlex - 15 mg/pen | somatropin | 02334879 | Growth hormone deficiency | 21 Aug 2014 | Within Guidelines |
2014 | Otsuka Canada Pharmaceuticals | Abilify Maintena - 300 mg/vial | aripiprazole | 02320864 | Schizophrenia | 27 Mar 2014 | Within Guidelines |
2014 | Otsuka Canada Pharmaceuticals | Abilify Maintena - 400 mg/vial | aripiprazole | 02420872 | Schizophrenia | 27 Mar 2014 | Within Guidelines |
2014 | Paladin Labs Inc. | Veregen - 100 mg/g | sinecatechins | 02411849 | Genital warts | 4 Jul 2014 | Within Guidelines |
2014 | Paladin Labs Inc. | Antizol - 1 g/mL | fomepizole | 02242980 | Antidote for ethylene glycol | 2 Nov 2006 (patented 10 Jun 2014) | Subject to Investigation |
2014 | Pfizer Canada Inc. | Irinotecan - 20 mg/ml | irinotecan hydrochloride trihydrate | 02410419 | Metastatic colorectal cancer | 11 Mar 2014 | Subject to Investigation |
2014 | Pfizer Canada Inc. | Bosulif - 100 mg/tablet | bosutinib | 02419149 | Protein-tyrosine kinase inhibitor | 31 Mar 2014 | Within Guidelines |
2014 | Pfizer Canada Inc. | Bosulif - 500 mg/tablet | bosutinib | 02419157 | Protein-tyrosine kinase inhibitor | 31 Mar 2014 | Within Guidelines |
2014 | Pfizer Canada Inc. | Cytarabine - 100 mg/ml | cytarabine | 02406772 | Leukemia | 17 Jan 2014 | Within Guidelines |
2014 | Pfizer Canada Inc. | Cytarabine - 20 mg/ml | cytarabine | 02406764 | Leukemia | 17 Jan 2014 | Within Guidelines |
2014 | Pfizer Canada Inc. | Xeljanz - 5 mg/tablet | tofacitinib | 02423898 | Rheumatoid arthritis | 6 Jun 2014 | Within Guidelines |
2014 | Sanofi-Aventis Canada Inc. | Zaltrap - 200 mg/vial | aflibercept | 02421089 | Metastatic colorectal cancer | 8 May 2014 | Within Guidelines |
2014 | Sanofi-Aventis Canada Inc. | Zaltrap - 100 mg/vial | aflibercept | 02421070 | Metastatic colorectal cancer | 8 May 2014 | Within Guidelines |
2014 | Sunovion Pharmaceuticals Canada Inc. | Latuda - 20 mg/tablet | lurasidone hydrochloride | 02422050 | Schizophrenia | 29 Apr 2014 | Within Guidelines |
2014 | Sunovion Pharmaceuticals Canada Inc. | Aptiom - 200 mg/tablet | eslicarbazepine acetate | 02426862 | Epilepsy | 9 Oct 2014 | Within Guidelines |
2014 | Sunovion Pharmaceuticals Canada Inc. | Aptiom - 400 mg/tablet | eslicarbazepine acetate | 02426870 | Epilepsy | 9 Oct 2014 | Within Guidelines |
2014 | Sunovion Pharmaceuticals Canada Inc. | Aptiom - 600 mg/tablet | eslicarbazepine acetate | 02426889 | Epilepsy | 9 Oct 2014 | Within Guidelines |
2014 | Sunovion Pharmaceuticals Canada Inc. | Aptiom - 800 mg/ tablet | eslicarbazepine acetate | 02426897 | Epilepsy | 9 Oct 2014 | Within Guidelines |
2014 | Sunovion Pharmaceuticals Canada Inc. | Latuda - 60 mg/tablet | lurasidone hydrochloride | 02413361 | Schizophrenia | 14 Mar 2014 | Within Guidelines |
2014 | Takeda Canada Inc. | Nesina - 12.5 mg/tablet | alogliptin benzoate | 02417197 | Diabetes | 30 Apr 2014 | Within Guidelines |
2014 | Takeda Canada Inc. | Nesina - 25 mg/tablet | alogliptin benzoate | 02417200 | Diabetes | 30 Apr 2014 | Within Guidelines |
2014 | Takeda Canada Inc. | Nesina - 6.25 mg/tablet | alogliptin benzoate | 02417189 | Diabetes | 30 Apr 2014 | Within Guidelines |
2014 | Takeda Canada Inc. | Kazano 12.5/1000 - 1012.5 mg/tablet | alogliptin benzoate/metformin hydrochloride | 02417235 | Diabetes | 30 Apr 2014 | Within Guidelines |
2014 | Takeda Canada Inc. | Kazano 12.5/500 - 512.5 mg/tablet | alogliptin benzoate/metformin hydrochloride | 02417219 | Diabetes | 30 Apr 2014 | Within Guidelines |
2014 | Takeda Canada Inc. | Kazano 12.5/850 - 862.5 mg/tablet | alogliptin benzoate/metformin hydrochloride | 02417227 | Diabetes | 30 Apr 2014 | Within Guidelines |
2014 | Teva Canada Innovation | Fentora - 100 mcg/tablet | fentanyl citrate | 02408007 | Pain | 14 May 2014 | Within Guidelines |
2014 | Teva Canada Innovation | Fentora - 200 mcg/tablet | fentanyl citrate | 02408015 | Pain | 14 May 2014 | Within Guidelines |
2014 | Teva Canada Innovation | Fentora - 400 mcg/tablet | fentanyl citrate | 02408023 | Pain | 14 May 2014 | Within Guidelines |
2014 | Teva Canada Innovation | Fentora - 600 mcg/tablet | fentanyl citrate | 02408031 | Pain | 14 May 2014 | Within Guidelines |
2014 | Teva Canada Innovation | Fentora - 800 mcg/tablet | fentanyl citrate | 02408058 | Pain | 14 May 2014 | Within Guidelines |
2014 | UCB Canada Inc. | Neupro - 1 mg/patch | rotigotine | 02403897 | Parkinson’s disease (dopamine agonist) | 19 Dec 2013 | Within Guidelines |
2014 | UCB Canada Inc. | Neupro - 3 mg/patch | rotigotine | 02403919 | Parkinson’s disease (dopamine agonist) | 19 Dec 2013 | Within Guidelines |
2014 | Valeant Canada Lp | Jublia - 100 mg/g | efinaconazole | 02413388 | Antifungal agent | 21 Jul 2014 | Within Guidelines |
2014 | ViiV Healthcare Ulc | Triumeq 50/600/300 – 950 mg/tablet | dolutegravir/abacavir/lamivudine | 02430932 | HIV | 22 Oct 2014 | Within Guidelines |